MENADNA and ProPhase Labs (NASDAQ: PRPH) Wholly-Owned Subsidiary, Nebula Genomics, Announce Strategic Partnership to Enhance Genomic Testing in Jordan, Oman and Iraq
Summary
This pivotal collaboration designates MENADNA as the exclusive partner of Nebula Genomics in Jordan, Oman, and Iraq, with an ambitious plan for future expansion.This partnership, spearheaded by MENADNAs CEO, Dr. Bassam El Fahmawi, aims to bridge the significant gap in genomic testing within Jordan, Oman and Iraq. The partnership will bring unparalleled genomic sequencing and analysis to the regions healthcare ecosystem.Bioinformatics Excellence: Utilizing MENADNAs advanced bioinformatics pipeline, together with Nebula’s propriety reports, the partnership will refine and enhance genomic data quality, addressing the unique genetic makeup and health needs of the region.Addressing the GWAS Gap: The region represents a diverse genetic landscape that is currently underrepresented in global GWAS, which predominantly feature European ancestries. By combining Nebulas state-of-the-art sequencing technology with our specialized bioinformatics pipeline, we can provide more accurate, region-specific genomic insights. Our joint efforts will not only enhance patient care but also significantly contribute to the global understanding of genetic variations and their impact on health. Nebula provides comprehensive genomic analysis and insights enabling individuals in over 135 countries to access their detailed genetic information.For further information, please visit: MENADNA.com
Classifications
AskAI Classifications
LabelsLinked Companies
